CELL - AND EXOSOME - BASED LIQUID BIOPSY

Cell- and exosome-based liquid biopsy is now here. As a liquid biopsy company, BioFluidica has created the future of liquid biopsy by creating LiquidScan®. *LiquidScan isolates rare cells and exosomes, making diagnostics possible for cell- and exosome-based liquid biopsy.

*LiquidScan combines cutting-edge microfluidics, advanced immunoaffinity chemistries, automation hardware, and workflow optimization to put liquid biopsy within easier reach for precision medicine for multiple cancers and prenatal diagnostics testing.

THE FUTURE OF LIQUID BIOPSY

BioFluidica LiquidScan isolates and enriches rare cells and exosomes from liquid biopsy samples. LiquidScan can enrich CTCs or fetal cells (trophoblasts) from whole blood and exosomes from plasma, enabling rare cell-based and exosome-based liquid biopsy analysis.

*LiquidScan is for Research Use Only

RECENT BIOFLUIDICA NEWS

READ MORE NEWS
December 12 - 2025

BioFluidica Co-Founder Named to National Academy of Inventors

Biofluidica, Inc. Co-Founder Steven Soper has been named to the National Academy of Inventors for the third year in a…

READ MORE
April 2 - 2024

BioFluidica to Exhibit at AACR National Meeting, San Diego, CA ~ April 5 – 10, 2024

READ MORE
January 30 - 2024

BioFluidica Showcased Fetal Cell-Based DNA Test at #SMFM2024

READ MORE